The clinical definition of Parkinson's disease (PD) is based on cardinal motor features including bradykinesia as well as an additional symptom of tremor, postural instability, or rigidity. Evidence from neuropathological, imaging, and clinical research suggests a premotor, early phase of PD pathology. Further understanding of the earliest biomarkers of PD is crucial for the development of neuroprotective, disease modifying, cognitive, and psychiatric interventions. Recent research has explored early non-motor markers of PD pathology. This issue is especially timely as the International Parkinson and Movement Disorder Society has recently provided a research definition for prodromal PD which includes combinations of prodromal markers and risk factors aimed at identifying target populations for disease-prevention trials. In this review of early PD, we will outline early non-motor symptoms, early cognitive and neuropsychiatric features, neuropsychological assessment strategies, emerging evidence for early biomarkers, and treatment recommendations.
Introduction
Parkinson's disease (PD) ranks second as the most prevalent neurodegenerative disorder after Alzheimer's disease. Parkinson's disease is characterized by loss of dopaminergic neurons in the substantia nigra pars compacta (SNpc), although there is now strong evidence showing that the pathological process may begin in the periphery and brain stem before reaching the midbrain (Braak et al., 2003) . In industrialized countries, PD prevalence is estimated at 0.3% of the entire population and at about 1% in individuals over 60 years of age (Nussbaum & Ellis, 2003) . The population of individuals with PD is anticipated to double by 2030 (Dorsey et al., 2007) . Given the demographic shift in many developing countries toward aging populations and PD's increased incidence with age (Elbaz & Moisan, 2008) , attention is warranted as health care demands and disease burden increase. This paper is designed to summarize important fundamentals in the field and to highlight recent trends and advances for the general neuropsychologist, it is not intended to be an exhaustive review of current science on early PD. reflects longer medication duration (Arevalo, Jorge, Garcia, Scipioni, & Gershanik, 1997; Kostic, Przedborski, Flaster, & Sternic, 1991) .
As compared to younger patients, older PD patients demonstrate more cognitive impairment, higher rates of dementia, and a more rapid course of disease progression (Hietanen & Teräväinen, 1988; Marttila & Rinne, 1976) . In a study of serial assessments of cognition, Biggins et al. (1992) demonstrated that PD patients who developed dementia had longer disease duration and older age of onset. Advanced age of onset has also been shown to predispose patients to dementia or cognitive deficits earlier in the disease process (Locascio, Corkin, & Growdon, 2003; Stern, Marder, Tang, & Mayeux, 1993) .
Prodromal Symptoms
The fundamental signs used to confirm PD diagnosis include tremor, slowness of movement, rigidity, and postural instability. While diagnosis occurs with the onset of motor symptoms, prodromal non-motor symptoms may precede motor symptoms by 20 years. Parkinson's disease pathogenesis process is hypothesized to begin during the prodromal period in the peripheral and central nervous system as well as in dopamine neurons in the SNpc. Prodromal symptoms can include constipation, anosmia, depression, excessive daytime sleepiness, and rapid eye movement sleep behavior disorder (RBD; Elbaz & Moisan, 2008) . Additionally, visual changes and subtle cognitive changes may also be present at prodromal stages. Constipation can occur as early as 20 years before the onset of motor symptoms and RBD as early as 10 years prior.
In a recent review of prodromal markers of PD, Postuma and Berg (2016) identified anosmia, RBD, and constipation as the markers with the strongest evidence to predict conversion to PD. RBD, dopaminergic imaging, and subtle motor parkinsonism markers had the highest diagnostic strength. The time between marker onset and conversion to PD varied considerably, between 5 years for motor performance to greater than 20 years for autonomic symptoms. Importantly, screening for some markers is quite cost efficient and can involve self-report or questionnaires, while other markers require sophisticated scanning methodology. While the prodromal period may provide an opportunity for early intervention once reliable identification methods have been developed, sensitivity and specificity of the prodromal symptoms still needs to be determined (Chen et al., 2013) .
Neuropathology and Neuropsychological Correlates
PD pathogenesis begins with degeneration of select dopamine neurons, nigral Lewy bodies, and deterioration of the SNpc (Klingelhoefer & Reichmann, 2015) which precedes prodromal non-motor symptoms reviewed above including constipation and hyposmia. These prodromal symptoms are in line with the Braak staging system, which corresponds with different stages of PD (Braak et al., 2003; Del Tredici, Rüb, De Vos, Bohl, & Braak, 2002 ). Braak's hypothesis, now well validated and widely accepted, suggests that Lewy pathology progression in PD occurs in a systematic and staged spread of α-synuclein, and that these stages correspond with clinical features of the disease. The progression of PD pathology through stages has been confirmed by evidence of pathology in healthy neurons grafted into PD patients' brains (McCann, Cartwright, & Halliday, 2016) . This process is thought to begin in the enteric nervous system (ENS) or olfactory bulb and subsequently move to the substantia nigra and central nervous system. Given the origination in the ENS, the Braak stages point toward environmental factors influencing PD pathogenesis (Reichmann, 2011) , a theory that is supported by animal and epidemiological evidence. During the presymptomatic Sages 1-2, pathology is limited to the medulla oblongata/pontine tegmentum and olfactory bulb/anterior olfactory nucleus. The substantia nigra and regions of the midbrain and forebrain are the sight of pathological change in Stages 3-4, at which point PD motor symptoms are likely to appear. More clinical features manifest in Stages 5-6 when pathology enters the neocortex (Braak, Ghebremedhin, Rüb, Bratzke, & Del Tredici, 2004 ).
Braak Stages and Prodromal PD
Although there is controversy surrounding the degree to which dopaminergic loss leads to the clinical expression of the disease, it has been estimated that cardinal motor signs begin to manifest following a 50%-80% reduction of nigral dopamine (Dauer & Przedborski, 2003; Meissner, 2012) . In the Braak staging model, motor signs begin at approximately Stage 3; however, at that point the neuropathological process involving the olfactory system is already under way. The prodromal symptoms reviewed above (e.g., olfactory disturbances, RBD, and constipation) are associated with extensive degeneration outside of the substantia nigra, and even outside of the brain. Thus prodromal risk factors are worthy of considerable attention in the course of disease modifying or neuroprotective interventions (Meissner, 2012) .
In a study of PD patients, Braak, Rüb, Steur, Del Tredici, and De Vos (2005) correlated Braak stages with MMSE scores, suggesting that cognitive status corresponds to neuropathological changes. Based on MMSE scores, four subgroups were identified which ranged from non-significantly impaired to severely impaired. Each of the subgroups MMSE scores were significantly correlated with Braak Stages 3-6. These data provide confirmatory evidence showing that the likelihood of developing dementia increases as the neuropathological markers of the disease progress (Braak, Rüb, & Del Tredici, 2006) .
Biomarkers of Early PD
While there is not a definite biomarker of PD, there is a clear need for early, sensitive, and specific diagnostic biomarkers to allow for early intervention strategies (Miller & O'Callaghan, 2015; Sharma et al., 2013) . In their review, Sharma et al. (2013) classified biomarkers as clinical, biochemical, genetic, proteomic, or neuroimaging. Early premotor biomarkers include hyperechogenicity of substantia nigra, olfactory and autonomic dysfunction, depression, hyposmia, REM sleep disorder, and impulsive behavior. Discernible deterioration of the substantia nigra and diminished striatal dopamine happen before cardinal motor signs appear. Clinical symptoms therefore appear slowly and frequently in an intermittent pattern in early PD. In individuals with clear risk for developing PD, Positron Emission Tomography (PET) scans can be used in early PD to detect substantia nigra deterioration; however, this form of neuroimaging is costly.
Given that non-motor and risk biomarkers are evident in the prodromal period of the PD process, there is a strong need for a clear understanding of the relationship between positive family history of PD, hyperechogenicity of the SN, and premotor biomarkers (Sharma et al., 2013) . In a sample of 1,149 volunteers, Liepelt-Scarfone et al. (2011) examined whether positive family history of PD (faPD+), hyperechogenicity of the substantia nigra (SN+), and olfactory dysfunction were examined in relationship to putative premotor biomarkers. Among this sample, 880 had none of the risk markers (76.6%), 143 individuals (12.4%) had SN+, 84 (7.3%) were classified as faPD+ and 42 (3.7%) individuals had both risk factors. Olfactory dysfunction and mild motor impairment was most prevalent in the SN+ subsample. Individuals with two risk factors were most likely to have depression. SN+ individuals with or without concurrent faPD+ showed a collection of premotor symptoms; however, this was not seen in the faPD+ only group. Liepelt-Scarfone et al. (2011) concluded that the overall profile of non-motor biomarkers differs in SN+ and/or faPD+ participants, with the SN+ group demonstrating the greatest association with premotor biomarkers. Therefore, SN+ may be an especially important early indicator for the PD degenerative process. Postuma and Berg (2016) reviewed possible markers for conversion to PD from the prodromal stage. Specifically, the authors identified clinical non-motor markers, clinical motor markers, neuroimaging markers, and tissue biomarkers during the prodromal stage. Markers with a high level of evidence include olfactory loss, REM sleep behavior disorder, constipation, and depression and anxiety. Moderate evidence was found for somnolence, orthostatic hypertension, subtle parkinsonism, quantitative motor testing, and substantia nigra hyperechogenicity. Urinary dysfunction, erectile dysfunction, color vision loss, dopaminergic PET/SPECT abnormalities, PD-related SepECT/ PeT, hippocampal hyperfusion, electrocardiogram beatto-beat variability, and α-synuclein gastrointestinal biopsy were identified as having a low level of evidence as prodromal markers. The authors note that greater specificity of prodomal biomarkesrs and the evidence for the likelihood that they convert to PD will pave the way for clinical trials of neuroptroctective therapy in early stages of PD.
Traditional Methods for Measuring PD progression
The Unified Parkinson's Disease Rating Scale (UPDRS) and The Hoehn and Yahr Staging Scale (HY) remain the gold standards in the field for measuring motor impairment in PD.
UPDRS. The UPDRS, first developed in the 1980s, is one of the most frequently used rating scales for PD. The scale was created to provide a comprehensive and flexible method of monitoring PD-related disability and impairment (Movement Disorder Society Task Force on Rating Scales for Parkinson 's Disease, 2003) . While the UPDRS has been investigated in studies of early, mild, moderate, and severe PD, prior studies have shown that the scale may not be as sensitive to mild PD symptoms and is skewed toward moderate and severe impairments (Johnels, Ingvarsson, Thorselius, Valls, & Steg, 1989) . Moreover, studies examining neuroprotective factors in early PD have demonstrated that the scale's floor effects limit its usefulness for detecting differences in impairment in early stages of PD (Movement Disorder Society Task Force on Rating Scales for Parkinson's Disease, 2003) . Some studies adapted the use of 0.5 increments to adjust for UPDRS floor effects (Richards, Marder, Cote, & Mayeux, 1994) . The MDS attempted to address these issues in the MDS-UPDRS, a modified version of the UPDRS (Goetz et al., 2008) . The modified version focuses more on non-motor elements of PD, emphasizes mild impairments (e.g., distinguishing between "slight" and "mild" and collapsing "severe" and "marked" into a single severe rating), and involves the participation of caregivers for the assessment of non-motor symptoms and motor experience in daily activities.
HY Staging Scale. The HY was created to be a simple yet descriptive rating scale for estimating clinical function in PD that characterizes both impairment and disability (Goetz et al., 2004) . The HY scale is useful in capturing the clinical stages of PD both with and without levodopa treatment. Progression in HY stages correlates with motor decline and diminished quality of life. Limitations of this scale include a predominant focus on unilateral versus bilateral presentation as well as reflex impairment while neglecting the non-motor aspects of PD. Furthermore, not all PD presentations are covered by the scale, leading 65% of movement disorder specialists to feel that the scale does not represent their patients well (Goetz et al., 2004) . Other specific criticisms include its lack of attention to the entire PD clinical spectrum (e.g., all aspects of disability) and that the categories are overly broad and do not progress in a linear fashion. Despite these drawbacks, the HY scale is broadly applied, with "mild" or "early" stages operationally defined as Stage 1 or 2, and advanced disease has been defined as Stages 4 and 5. There is no clear operational definition of Stage 3 as moderate PD because balance difficulties, the characteristic symptom of moderate PD, lack a standardized definition.
Taken together, traditional methods for measuring PD progression do not provide a clear clinical picture of "early PD." There remains seemingly great heterogeneity across scale scores and years of disease and neither of the scales comprehensively capture prodromal features of PD.
Cognitive and Neuropsychiatric Features in Early PD: Past and Current Perspectives
Neuropsychological correlates in early PD have been a subject of interest dating back over many decades (Mayeux, Stern, Rosen, & Leventhal, 1981) . Initial studies examining cognition in PD focused on global cognitive changes using standardized mental status screenings such as the MMSE. Subsequently, neuropsychological research shifted to specific cognitive domains. Examining cognitive changes in early PD is important for monitoring mental status over time, linking motor symptoms with cognition, and disentangling the effects of medication from later stage PD. The sections below outline the evolution of cognitive research in early PD by domain.
Executive Functions
In an early investigation of cognitive correlates of early stages of PD, Levin, Llabre, and Weiner (1988a) identified patients who had been diagnosed with PD for less than a 2-year-period and compared their performance on a neuropsychological battery to controls. Underlying PD patients' performance across all domains were deficits in initiating, sustaining and shifting cognitive sets, forming abstractions, and efficient problem-solving. It was concluded that less than 2 years' duration of PD is associated with significant neuropsychological decline, particularly on tasks requiring frontal lobe involvement. Levin et al. (1988a) concluded that early neuropsychological deficits are a direct consequence of impaired dopamine production, which in turn, directly impact the dopaminergic pathways that project to frontal lobes. Furthermore, they suggested that dopamine depletion affecting nigrostriatal pathways was the most likely explanation for the pattern of deficits similar to those of frontal lobe patients.
More recently, in a meta-analysis of executive dysfunction in early PD, Kudlicka, Clare, and Hindle (2011) gathered data from 33 studies including non-demented, unmedicated patients in HY Stages I-III, that examined PD patients' performance on neuropsychological measures of executive function. As compared to controls, PD patients showed impairments in fluency tasks (semantic, phonemic, and category switching), digit span backward subtest, trail making tests, and measures from the Wisconsin Card Sorting and Stroop tests. Effect sizes were similar across executive function measures. In addition to the severity of executive deficits, progression of PD also impacts the nature of executive deficits (Dirnberger & Jahanshahi, 2013) . Executive functions rely on several cognitive processes that involve structures other than frontostriatal circuitry, including the temporal lobes. Thus, the progressive decline in executive functions early in PD may reveal the involvement of other non-dopaminergic systems (Bassetti, 2010; Dirnberger & Jahanshahi, 2013) .
Visuospatial Skills
Deficits in visuospatial skills can predict future PD dementia (Hughes et al., 2000; Janvin, Aarsland, Larsen, & Hugdahl, 2003) and have also been shown to have a mild association with post-operative outcomes following deep brain stimulation surgery (Abboud et al., 2015) . To appropriately measure visuospatial skills in PD, tasks should not involve a motor component and be untimed so that the need for adept motor skills does not confounds results (Levin & Katzen, 2005) . The judgment of line orientation test (JLO) is among the visuospatial tasks recommended by the MDS task force in the assessment of mild cognitive impairment in PD (PD-MCI) and does not include a motor component (Litvan et al., 2012) . Levin et al. (1991) found that performance on a comprehensive battery of six visuospatial tasks, performance declined as a function of disease duration (1-4 years, 5-10 years, or greater than 10 years) with the pattern depending on the presence of dementia. As with observed language deficits, visuospatial deficits in early PD may reflect involvement of executive functions and frontostriatal circuitry, rather than a pure visuospatial difficulty. Similarly, Farina et al. (2000) suggested that visuospatial deficits are evident in early PD when the tasks incorporate set shifting and executive processes.
Language
Levin and Katzen (2005) noted that, even in advanced PD, language skills are largely preserved with little existing literature utilizing comprehensive batteries that found evidence for language deficits. When there is evidence for language deficits, they are usually subtle and involve executive aspects (Grossman, Lee, Morris, Stern, & Hurtig, 2002) . For example, PD patients have greater perseverative intrusions due to difficulty set shifting under time pressure (Lees & Smith, 1983) , difficulty with planning linguistic sequences (Illes, 1989) , difficulty with answering syntactically embedded questions (Carvell, Gollomp, Stern, & Hurtig, 1991) , and mild deficits in language expression, object word fluency, and category alternation (Cooper, Sagar, Jordan, Harvey, & Sullivan, 1991) . Levin, Llabre, and Weiner (1989) did not find differences in performance between early PD patients and matched controls in fund of vocabulary, word retrieval, and verbal fluency. Early PD patients performed worse on categorical fluency and recitation of the months backward. In sum, observed language deficits in early PD are typically highly circumscribed, and involve executive components such as fluency and organization. Therefore, there is scant evidence suggesting pure language deficits early in the disease process that do not involve frontal circuitry.
Memory
Taylor, Saint-Cyr, and Lang (1990) compared patients newly diagnosed with PD with age matched controls and found that PD patients showed worse recollection of semantically-related words, were less efficient at using clustering strategies to facilitate learning, and showed worse performance on immediate recall conditions. Moreover, patients with PD were more susceptible to interference effects and demonstrated worse source memory. Taylor et al. (1990) concluded that PD patients' memory deficits stem from inefficient learning and organization of the memoranda due to frontostriatal dysfunction. Cooper, Sagar, and Sullivan (1993) also showed that recently diagnosed PD patients performed worse than matched controls on backward digit span, logical memory immediate and delayed conditions, and paired associates learning. Fischer, Kendler, and Goldenberg (1990) , Stoffers, Berendse, Deijen, and Wolters (2003) , and Pillon et al. (1997) found that patients with early PD showed worse recency memory for visual memoranda, general visuospatial memory, and memory for spatial locations respectively. Levin and Katzen (2005) emphasized that memory tasks recruit several cognitive processes, therefore, poor performance on memory tasks may not reflect a memory deficit per se, but rather may be indicative of poor planning, sequencing, and organization during encoding, making it difficult to maintain and later recall a stimulus. Thus, mounting evidence suggests that working memory deficits may underlie memory deficits in early stage PD, (i.e., the ability to hold information online, in the face of interference for the purpose of future action) (Fuster, 1988) . Working memory processes have been shown to recruit the dorsolateral prefrontal cortex (DLPFC), which may underlie poor memory performance in PD.
Current Perspectives: Dual Syndrome Hypothesis for Cognitive Impairment
While PD is associated with dysfunction of frontostriatal circuits underlying executive systems, accumulating recent evidence indicates multiple affected domains (Aarsland & Kurz, 2010; Elgh et al., 2009; Hely, Reid, Adena, Halliday, & Morris, 2008; Janvin, Larsen, Aarsland, & Hugdahl, 2006; Pedersen, Larsen, Tysnes, & Alves, 2013) . This conceptualization for categorizing cognitive impairment in PD emerges from the Cambridgeshire Parkinson's Incidence from GP to Neurologist (CamPaIGN) Study (Foltynie, Brayne, Robbins, & Barker, 2004) . The CamPaIGN study is the first longitudinal study of an incident PD cohort that includes neuropsychological and genetic analyses at the outset of the study . Two PD phenotypes have evolved from these studies, a frontal executive dysfunction and a posterior cortical dysfunction, the first demonstrating impaired language and semantic fluency and the latter impaired visuospatial orientation and pentagon copying (Williams-Gray et al., 2009; Williams-Gray, Foltynie, Brayne, Robbins, & Barker, 2007) . Disrupted dopaminergic frontostriatal networks are purported to underlie executive deficits. Non-dopaminergic dysfunction, cortical Lewy Body deposition, and possible AD-type pathology are thought to underlie posterior cortical impairments . The authors propose that even in early PD, subgroups can be identified that may point toward regional differences in the underlying neuropathological process. Five-year follow-up in the CamPaIGN study demonstrated that early deficits on frontostriatal tasks were not related to subsequent dementia risk, rather a dissociation was found between semantic and phonemic fluency, with the temporal lobe component being predictive of progression to dementia, rather than the common frontally-based strategic recall factor (WilliamsGray et al., 2007 (WilliamsGray et al., , 2009 . Frontally-based deficits were also shown to have a common genetically determined variation in COMT activity thought to be modulated by cortical dopamine levels, whereas deficits on tasks with a more temporal and parietal lobe bases were not affected by COMT, and have a non-dopaminergic etiology.
The dynamic nature of neurodegeneration, neurotransmitter loss, and progressive neuropathology supports The Dual Syndrome hypothesis of cognitive deficits in PD (Goris et al., 2007; Kehagia, Barker, & Robbins, 2010; Winder-Rhodes et al., 2013) . The hypothesis proposes that two syndromes exist in PD; namely, frontostriatal dopaminergic dysfunction that impairs planning, working memory, response inhibition and attention control and posterior cortical pathology that impairs visual mnemonic and semantic functions. In testing this hypothesis, the Cognitive Impairment in Cohorts with Longitudinal Evaluation (ICICLE-PD) study examined recently diagnosed PD patients using three neuroimaging paradigms (Tower of London, Spatial Rotations, and Memory Encoding Tasks) spanning frontostriatal and parieto-temporal functions as well as genotyping for three polymorphisms associated with cognitive change in PD (Nombela, Bustillo, Castell, Medina, & Herrero, 2011) . These authors found anatomical, functional, genetic, and behavioral data and supported the dual syndrome hypothesis.
Mild Cognitive Impairment in PD
Though cognitive deficits in PD have been long recognized, the concept of PD-MCI is a relatively recent entity. Mild cognitive impairment is often thought of as the transition period between normal cognitive aging and early dementia. An MCI diagnosis can function as a red flag that identifies individuals at risk for conversion to dementia. In PD, early identification of cognitive impairment is crucial for intervention as well as contributing to epidemiologic and prognostic literature (Geurtsen et al., 2014; Litvan et al., 2011) . The MDS has proposed diagnostic criteria for PD-MCI (Litvan et al., 2011 (Litvan et al., , 2012 . PD-MCI inclusion criteria consist of: (i) an established PD diagnosis, (ii) cognitive decline as reported by patient or caregiver or observed by a clinician, and (iii) cognitive deficits which do not interfere significantly with functional independence. PD-MCI exclusion criteria include: (i) Parkinsonism other than idiopathic PD, (ii) meeting MDS criteria for PDD, and (iii) other explanations for cognitive decline. The MDS PD-MCI criteria consist of two levels, Level I (based on an abbreviated assessment) and Level II (based on comprehensive neuropsychological evaluation permitting MCI subtyping) Litvan et al., 2012) .
Thus, in its recommendations for diagnostic procedures for PD-MCI, the MDS Task Force suggests a multi-tiered approach and sets forth practical guidelines (Litvan et al., 2012) . The requirements for diagnosis of PD-MCI by Level I are impairments on measures of global cognitive ability, or impairments on a limited neuropsychological battery with only one test per cognitive domain. Relevant cognitive domains include executive function, language, memory, and visuospatial functions (examples of possible tests provided in Table 1 ). Impairment on two tests satisfies Level I PD-MCI criteria. The task force recommends formal neuropsychological testing for diagnosis of PD-MCI by Level II including two tests for each of the five cognitive domains above. Impairment based on MDS criteria should be evident in at least two tests in either one cognitive domain or across domains. Level II testing allows for sub-type classification as either single or multiple domain.
In a recent review of PD-MCI, Goldman, Aggarwal, and Schroeder (2015) note the prevalence of studies in both incident and prevalence cohorts of pre and post MDS PD-MCI criteria. These investigations in newly diagnosed PD patients using MDS PD-MCI Level II criteria found increased frequency in multiple domain impairment (90%, 93%, 91.2%, and 65%) compared to single domain impairment (Broeders et al., 2013; Cholerton et al., 2014; Goldman et al., 2013; Marras et al., 2013) . Cognitive impairment is common in PD, with approximately 25% of PD patients without dementia having MCI ) and up to 80% of patients converting to dementia (Dauer & Przedborski, 2003; Litvan et al., 2012) .
In the ICICLE-PD study, Yarnall et al. (2014) described the frequency of MCI and the associations with a panel of biomarkers. The authors found 42.5% of the study population to meet Level II MDS PD-MCI criteria at 1.5 SDs below normative means. This proportion is higher than those reported in previous studies (14.8%-36%); however, these prior studies did not employ the MDS PD-MCI criteria which may be less stringent than other definitions Foltynie et al., 2004; . The PD-MCI II individuals also had significantly lower levels of CSF β-amyloid 1-42 (Aβ42) and 1-40 (Aβ40).
Consistent with other investigations, individuals with PD-MCI were also found to have memory impairment Foltynie et al., 2004) . Other prominent investigations of PD-MCI have found significant impairments in executive functions that are frontally mediated (Caviness et al., 2007; Foltynie et al., 2004) . In a follow-up study of the ICICLE-PD cohort, longitudinal analyses revealed that patients with PD-MCI had more extensive atrophy and cortical thinning as compared to those with PD without cognitive impairment (PD-NC) (Mak et al., 2015) . Specifically, at baseline, patients with PD-MCI had reduced cortical thickness in frontal and temporo-pareital cortices as well as atrophy in the nucleus accumbens and hippocampus. At 18 months follow-up, PD-MCI patients showed an increased percentage of thinning and atrophy in these regions as compared to PD-NC and healthy controls. Several prior studies have also reported reduced cortical thickness and a decrease of gray matter in the nucleus accumbens over time (Hanganu et al., 2014; Pereira et al., 2014) . This study provides anatomic biomarker validity to the MDS task force PD-MCI criteria by investigating structural differences in PD-MCI and PD-NC. Further evidence to support the validity of PD-MCI comes from a prospective population-based study in an incident cohort of PD showing that more than 25% of patients with MCI at PD diagnosis developed dementia at 3-year follow-up as compared to the less than 1% of those without MCI at PD diagnosis (Pedersen et al., 2013) . PD-MCI terminology is not without controversy (Goldman et al., 2015; Litvan et al., 2011 ). Tröster (2008 argued that although there is clear evidence of decline in executive function early in PD, and executive deficits are often precursors to dementia, the term MCI should not be extended to PD without careful consideration of cognitive symptoms in prodromal PD. Moreover, the PD-MCI criteria are in need of validation. Tröster (2008) discussed the importance of considering other prodromal features and early biomarkers and argued that an understanding of the constellation of early cognitive deficits will further efforts for early diagnosis and provide greater opportunity for neuroprotective treatments. Barker and Williams-Gray (2014) argue that as a diagnostic category, PD-MCI may be overly simplistic, as the term suggests a single etiology and therefore excludes cognitive deficits due to comorbid conditions (e.g., concurrent Alzheimer's disease, effects of drug therapies, depression, fatigue, and low premorbid functioning). Causes of cognitive deficits in PD are argued to have a multifactorial basis, some of which result in dementia; thus a single label of PD-MCI does not accurately capture all possible pathologies. Future research should examine underlying causes of cognitive deficits in PD, how they are interconnected, and how they progress to dementia. Such research could enable more fruitful trials of disease-modifying therapies aimed at slowing down the dementing process in PD.
Neuropsychiatric Features of PD
Substantial evidence points toward neuropsychiatric features in early PD that impact quality of life, day-to-day functioning, and caregiver burden (Aarsland, Marsh, Schrag, 2009 ). Bronnick, Aarsland, and Larsen (2005) found that neuropsychiatric disturbances in PD tend to cluster in five groups. Among a sample of 139 patients, the largest group showed mildly depressive symptoms, followed by a group with hallucinations, then exclusive sleep disturbance, the fourth group showed apathy, anxiety, and depression, and the fifth and smallest group had high scores on several neuropsychiatric inventory items. The most common neuropsychiatric features of PD and their impact on quality of life are reviewed below. These include depression, anxiety, apathy, fatigue, and psychotic symptoms.
Depression and Anxiety
Depression symptoms precede motor symptoms in 30% of PD patients, making depression an important prodromal marker of PD. Depression in early PD has a significant impact on quality of life in early PD. Parkinson himself documented depressive symptoms in his original essay. As noted by Postuma et al. (2012) , dopamine (SNpc), serotonin (raphe nuclei), and noradrenaline (locus coeruleus) dysfunction are all implicated in depression as well as in Braak Stage 2, which is characterized by worsening pathology in the dorsal motor nucleus as well as additional lesions in the raphe nuclei and gigantocellular reticular nucleus (Braak et al., 2003 (Braak et al., , 2004 . Postuma et al. (2012) noted that the shared symptoms in PD and depression make an accurate depression diagnosis more difficult. However, despite diagnostic complications, 35%-50% of patients with PD have comorbid depression. Prevalence rates vary in the literature due to difficulties in clear depression diagnoses. Importantly, as with patients without neurodegenerative diseases, depression contributes to less efficient cognitive functioning. However, this relationship is also been challenged (McClintock, Husain, Greer, & Cullum, 2010) .
In a sample of patients with moderate to severe PD, Nation, Katzen, Papapetropoulos, Scanlon, and Levin (2009) identified groups of patients with diagnostic depression, subthreshold depression, and non-depression and compared the groups on demographic variables. Patients with subthreshold depression were approximately 5 years younger than non-depressed patients, but otherwise showed no difference in disease stage. The group of subthreshold depression patients' mood symptoms tended to overlap with PD symptoms, thus emphasizing the difficulty in distinguishing the two diagnoses. Levin, Llabre, and Weiner (1988b) emphasized the importance of accurate diagnoses and the use of the Beck Depression Inventory (BDI), which includes many items that involve somatic features, making sensitivity to depression as opposed to features of PD difficult. However, an item analysis of the BDI in PD patients indicated that the BDI can detect depression in PD with strong internal consistency reliability.
Up to 40% of PD patients are affected by anxiety (Leentjens et al., 2008; Nuti et al., 2004; Richard, 2005) . Anxiety and depression are often, but not always, comorbid and can be observed in sync with PD motor fluctuations. The anxiety disorders most commonly associated with PD are panic attacks (usually during off periods), generalized anxiety disorder (GAD), and specific and social phobias . If anxiety symptoms occur only in off periods, medication adjustment may alleviate symptoms.
Fatigue and Apathy
Both fatigue and apathy are major contributors to diminished quality of life in PD and are often accompanied by mood symptoms. Fatigue is also an important prodromal symptom. In PD, apathy and fatigue are believed to result from disruption of basal ganglia function and frontal striatal connections (Dujardin et al., 2007) . noted that proper identification of these symptoms inevitably leads to improved quality of life; however, there are few studies that have specifically addressed this issue, and more research in this area is needed in order to identify effective interventions.
Fatigue is often a prodromal symptom of PD, appearing before cardinal motor symptoms (Lou, Kearns, Oken, Sexton, & Nutt, 2001) . Though measurements of fatigue tend to vary, it is reported by up to one-third of PD patients as the most debilitating symptom (Friedman et al., 2007) and has a prevalence of 32%-58% (Herlofson & Larsen, 2003) . As described by Lou et al., (2001) , fatigue can be described as either central or peripheral. The latter form is characterized by diminished energy due to muscular fatigue. Central fatigue is more clinically relevant and is characterized by "an abnormal degree of persistent tiredness, weakness, or exhaustion that is mental, physical or both in the absence of motor or physical impairment" . Central fatigue can be divided into physical and mental, which are difficult to differentiate due to their subjective experience.
Apathy involves behavioral, emotional, and cognitive characteristics that manifest as diminished interest in goal-directed behaviors, indifference, and flattened affect (Marin, 1997) . Apathy has primarily been identified using rating scales with prevalence rates varying between 17% and 70% (Aarsland et al., 1999; Pluck & Brown, 2002) . Factors that influence apathy include depression, level of cognitive impairment, assessment tool employed, and the individual rater (Kirsch-Darrow, Fernandez, Marsiske, Okun, & Bowers, 2006) . Few studies have followed the longitudinal course of apathy. The literature has focused on lack of motivation and diminished emotional responsiveness as core features of apathy. Patients with clinical apathy tend to show decreased spontaneous engagement or premature withdrawal from engagements, absence of care for one's own health, and little exploration of novel experiences. Apathy results in inactivity, functional decline, and hence greater overall disability. In PD, apathy is often associated with bradyphrenia, cognitive impairment (global), and executive dysfunction (Kirsch-Darrow et al., 2006; Pluck & Brown, 2002) .
Psychotic Symptoms
De la Riva, Smith, Xie, and Weintraub (2014) investigated psychiatric symptoms in early untreated PD patients and found psychosis and apathy to increase over time. Psychotic symptoms (e.g., visual or auditory hallucinations, illusions, and passage or presence phenomenon) occur frequently in PD . Patients may experience both visual and auditory hallucinations, with visual symptoms being more common. Katzen et al. (2010) categorized 152 idiopathic PD patients based on the presence or absence of hallucinations and then based on whether the hallucinations were visual-only or multimodal. All patients were administered a comprehensive neuropsychological battery. Participants with hallucinations performed worse on select neuropsychological measures and exhibited greater mood symptoms; however, there were no differences between visual-only and multimodal hallucination groups. Katzen et al. (2010) therefore concluded that patients with multimodal hallucinations are not at risk for greater neuropsychological impairment. While few longitudinal studies exist, psychotic symptoms can be progressive. Visual hallucinations may or may not be accompanied by insight, with the lack of insight group typically showing greater cognitive impairment.
The loss of dopamine is hypothesized to underlie some neuropsychiatric symptoms in PD (Remy, Doder, Lees, Turjanski, & Brooks, 2005) . Hypodopaminergic states are hypothesized to be associated with apathy, depression, and anxiety. Conversely a hyperdopamingeric state may precipitate the onset of psychosis, impulse control disorders, and excessive daytime sleepiness (Burn & Tröster, 2004; Weintraub et al., 2010) .
Neuropsychological Assessment Strategy
Developing a neuropsychological test battery requires careful consideration because not all traditional neuropsychological measures are sensitive to early cognitive changes in PD. While the MMSE is often relied upon by neurologists and neuropsychologists in the diagnosis of dementia, it has not been proven to be as diagnostically helpful in early PD. A review of batteries used by large clinical investigations (Deprenyl and Tocopherol Antioxidative Therapy of Parkinsonsism; Parkinson's disease Data Organizing Center; Parkinson's Progression Markers Initiative; National Institute of Neurological Disorders and Stroke Common Data Elements; and National Alzheimer's Coordinating Center Uniform Data Set) highlights a significant lack of agreement between test batteries used in PD research. Watson et al. (2013) developed The University of Pennsylvania and the University of Washington Udall Center's (Penn-UW) battery based on a review of existing research on PD batteries, the tests' psychometric properties, their research and clinical utility, their measurement of cognitive impairment and PD symptoms, and their testing burden. The authors recommend a multi-tiered approach to assessment (Table 1) , with the first level involving screening via the Montréal Cognitive Assessment (MoCA) for general cognition and the neuropsychiatric inventory (NPI) for behavioral symptoms. At this level, patients with severe impairment are given an alternative, the battery Dementia Rating Scale-2 (DRS-2). The second level of assessment includes domain specific cognitive tests and questionnaires focusing on psychiatric functioning. Importantly, Watson et al. (2013) acknowledged that additional and more detailed factors may need to be assessed depending on the specific clinical presentation of the patient or the goals of the given study. Therefore, they provide recommendations of supplemental tests for general cognition (Table 1 ). The recommended tests proposed by the MDS task force for evaluating PD-MCI Levels I and II, as described above, are also outlined in Table 1 . Importantly, a battery optimized for standardized research protocol may not serve the individual clinician who wishes to flexibly adapt a battery to individual clinical needs. However, the abovementioned batteries provide a valid starting point (Marras, Tröster, Kulisevsky, & Stebbins, 2014) . As noted previously in this review, inclusion of non-motor tests of cognitive function is essential to disentangle the cognitive from motor impairment. Similarly, computerized tests may underestimate cognitive performance in PD due to over-reliance on manual dexterity and speeded response times. A summary of assessment findings and recommendations for preclinical, prodromal, clinical, and PD-MCI is provided in Table 2 .
Treatment of Cognitive and Behavioral Issues in Early PD
Dopaminergic interventions for PD tend to have variable effects on executive functions (Dirnberger & Jahanshahi, 2013) . Specifically, dopaminergic intervention improves performance on executive function tasks mediated by the dorsolateral frontostriatal circuit (e.g., set shifting and planning). Conversely, medicated PD patients show impairments on tasks mediated by limbic and orbitofrontal circuits (e.g., conditional associative learning, reversal learning, reward learning, probabilistic classification learning, and risk taking paradigms). The topic of how dopaminergic medication affects social cognition is complex, likely because these tasks involve cortical as well as mesolimbic structures (Thaler et al., 2012) , not to mention a host of environmental variables that are difficult to document retrospectively or to follow prospectively.
Treatment of Psychiatric Symptoms PD
In a review of psychotropic drug interventions to treat neuropsychiatric etiologies in PD and Alzheimer's disease, Van der Schyf (2016) noted that treatments designed to directly address neuropsychological and psychiatric problems in early PD are limited. To date, several studies have examined the use of cholinesterase inhibitors (e.g., rivastigmine), which is suggested by the loss of cholinergic, dopaminergic, and noradrenergic innervations in PD. In one study examining rivastigmine's effects on attentional tasks and executive function, Bullock and Lane (2007) found positive treatment outcome in a sample with PD dementia. Maidment, Fox, and Boustani (2006) conducted a review of randomized, double-blind, placebo-controlled studies targeted at the effective of cholinesterase inhibitors in patients diagnosed with moderate to severe PD dementia. Rivastigmine was found to yield statistically significant improvements across outcome measures, including a 2.8 point improvement on the Alzheimer's disease Assessment Scale-Cognitive (ADAS-cog). Glutamate receptor modulator (memantine) has produced variable effects on neuropsychiatric deficits, indicating the need for more research in this area.
As described above, depression is a common symptom in early PD. Citalopram, escitalopram, sertraline, bupropion, trazodone, venlafaxine, mirtazapine, and duloxetine have all been shown to help with depression (Costa, Rosso, Maultasch, Nicaretta, & Vincent, 2012) . Amitriptyline, nortriptyline, and desipramine are tricyclic antidepressants that can be used to treat early depression in PD. However, anticholinergic associated with tricyclics may increase the risk of cognitive deterioration.
Other Forms of Intervention
To date, there is no effective pharmacological intervention for cognitive impairment deficits in PD. Vemuri, Fields, Peter, and Klöppel (2016) underscored the need for cognitive interventions in PD, especially given the negative impact of antiparkinsonian medication (e.g., levodopa and dopamine agonists) on cognition and behavior (Poletti & Bonuccelli, 2013) . In their review of cognitive interventions in PD and Alzheimer's disease, Vemuri et al. (2016) found that cognitive training studies have demonstrated improvements in working memory, processing speed, and executive functions. Cognitive rehabilitation strategies in PD have shown improvements in attention and quality of life. Imaging data of PD patients following cognitive training interventions has shown alterations in brain activation in primarily frontal and parietal areas corresponding with improved cognitive performance (Poletti & Bonuccelli, 2012) . Future work in this domain should be pointed toward rigorous longitudinal studies incorporating imaging to determine efficacy. In a review of 13 cognitive training studies between 2000 and 2014, Glizer and MacDonald (2016) found that training studies produced short-term moderate improvements in some cognitive functions, but that results showed inconsistencies across methodologies. They argue that future training studies Berg et al. (2013 Berg et al. ( , 2014 Berg et al. ( , 2015 , Stern et al. (2012) Marks the presence of neurodegenerative synucleinopathy without clinical symptoms, requires neurodegeneration, and risk alone does not suffice (e.g., carrying a known causative gene in the absence of neurodegeneration).
Diagnosis requires biomarkers using cerebrospinal fluid or imaging (e.g., hyperechogenicity of the SN, PET, SPECT, DAT, or novel MRI methods); however, biomarker methods need to be validated. Diagnostic assessment of prodromal PD Berg et al. (2013 Berg et al. ( , 2014 Berg et al. ( , 2015 , Elbaz and Moisan (2008) , Stern et al. (2012) , Levin and Katzen (2005) , Lou et al. (2001) , Postuma and Berg (2016) Presence of early non-motor signs and symptoms due to extranigral PD pathology. Symptoms can include fatigue, constipation, anosmia, depression, excessive daytime sleepiness, and RBD. Executive deficits are predominant.
Include clinical interview, sleep study, and neuropsychological testing to assess for executive dysfunction and depression. Note that no method exists to identify prodromal PD with 100% reliability. should clearly define participants' cognitive profile, have a larger sample size, be hypothesis driven, and clearly identify outcome measures of the training interventions.
Conclusions and Future Directions
As the population ages and the prevalence of PD increases, there will be an increased need to understand the biomarkers and neural circuitry underlying the initial cognitive and behavioral manifestations of the disease. This is especially true since interventions are likely to be most effective in the prodromal and early stage PD. PD-MCI has emerged as a construct for identifying early stage PD decline. However, variability in genetics, neurobiological substrates, and specific neuropathological etiological suggest the possibility of clinical phenotypes of PD. Refined therapeutic interventions for disease modification and symptomatic relief are still at large. Promising future endeavors toward this aim of early identification of individuals at higher risk for cognitive decline include the discovery of biomarkers (e.g., neuroimaging studies, cerebrospinal fluid markers, and genetics) that indicate level of disease progression, degree of cognitive impairment, and underlying pathology.
